Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas

Journal of Clinical Oncology

Volumn 14, Issue 1, 1996, Pages 25-34

  Combaret, V ^a   Gross, N ^a   Lasset, C ^a   Frappaz, D ^a   Peruisseau, G ^a   Philip, T ^a   Beck, D ^a   Favrot, M C ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CLINICAL PROTOCOL; GENE AMPLIFICATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEUROBLASTOMA; ONCOGENE C MYB; ONSET AGE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SOLID TUMOR;

EID: 0030030601     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.1.25     Document Type: Article

References (53)

1. Young JL Jr, Miller RW: Incidence of malignant tumors in US children. J Pediatr 86:254-258, 1975
2. Carlsen NLT: Neuroblastoma: Epidemiology and pattern of regression. Problems in interpreting results of mass screening. Am J Pediatr Hematol Oncol 14:103-110, 1992
3. Evans AE, D'Angio OJ, Propert K, et al: Prognostic factors in neuroblastoma. Cancer 59:1853-1859, 1987
4. Berthold F, Trechow R, Utsch S, et al: Prognosis factors in metastatic neuroblastoma. A multivariate analysis of 182 cases. Am J Pediatr Hematol Oncol 14:207-215, 1992
5. Berthold F, Kassenböhmer R, Zieschang J: Multivariate evaluation of prognostic factors in localized neuroblastoma. Am J Pediatr Hematol Oncol 16:107-115, 1994
6. Look AT, Hayes FA, Nitschke R, McWilliams NB, et al: Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Eng J Med 311:231-235, 1984
7. Christiansen H, Lampert F: Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma. Br J Cancer 57:121-126, 1988
8. Combaret V, Wang Q, Favrot MC, et al: Clinical value of N-myc oncogene amplification in 52 patients with neuroblastoma included in recent therapeutic protocols. Eur J Cancer Clin Oncol 24:1607-1612, 1989
9. Fong C-T, Dracopoli NC, White PS, et al: Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: Correlation with N-myc amplification. Proc Natl Acad Sci USA 86:3753-3757, 1989
10. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111-1116, 1984
11. Ladenstein R, Favrot MC, Lasset C, et al: Indication and limits of megatherapy and bone marrow transplantation in high-risk neuroblastoma: A single center analysis of prognostic factors. Eur J Cancer 29:947-956, 1993
12. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al: Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328:847-854, 1993
13. Bourhis J, De Vathaire F, Wilson GD, et al: Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res 51:33-36, 1991
14. Shimada H, Chatten J, Newton WA, et al: Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastomas and age-linked classification of neuroblastoma. J Natl Cancer Inst 73:405-416, 1984
15. Jackson GD, Buckley J, Bell JL: Multiple variants of the human lymphocyte homing receptor CD44 generated by insertion at a single site in the extracellular domain. J Biochem Cell Biol 267:4732-4739, 1992
16. Stamenkovic I, Amiot M, Pesando JM, et al: A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 56:1057-1062, 1989
17. Aruffo A, Stamenkovic I, Melnick M, et al: CD44 is the principal cell surface receptor for hyaluronate. Cell 61:1303-1313, 1990
18. Jalkanen ST, Bargatze RF, Herron LR, Butcher EC: A lymphoid cell surface involved in endothelial cell recognition and lymphocyte homing in man. Eur J Immunol 16:1195-1202, 1986
19. Miyake K, Underhill CB, Lesley J, Kincade PW: Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. J Exp Med 172:69-75, 1990
20. Huet S, Groux H, Caillou B, et al: CD44 contributes to T cell activation. J Immunol 143:798-801, 1989
21. Saint John T, Meyer J, Idzerda R, et al: Expression of CD44 confers a new adhesive phenotype on transfected cells. Cell 60:45-52, 1990
22. Arch R, Wirth K, Hofmann M, et al: Participation in normal immune responses of a metastasis inducing splice variant of CD44. Science 257:682-685, 1993
23. Günthert U, Hofmann M, Rudy W, et al: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65:13-24, 1991
24. Birch M, Mitchell S, Hart I: Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res 51:6660-6667, 1991
25. Heider KH, Hofmann M, Horst E, et al: A human homologue of the rat metastasis associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 120:227-33, 1993
26. Hofmann M, Rudy W, Tolg C, et al: CD44 splice variants confer metastatic behavior in rats: Homologous sequences are expressed in human tumor cell lines. Cancer Res 51:5292-5297, 1991
27. Rudy W, Hofmann M, Schwartzalbiez R, et al: The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants - Each one individually suffices to confer metastatic behaviour. Cancer Res 53:1262-1268, 1993
28. Sy MS, Quo YJ, Stamenkovic I: Inhibition of tumor growth in vivo with a soluble CD44 immunoglobulin fusion protein. J Exp Med 176:623-627, 1992
29. Horst E, Meijer DJKM, Radaszkievicz T, et al: Adhesion molecules in the prognosis of diffuse large-cell lymphoma: Expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia 4:595-599, 1990
30. Jalkanen S, Joensuu H, Söderström KO, et al: Lymphocyte homing receptor and clinical behavior of non-Hodgkin's lymphoma. J Clin Invest 87:1835-1840, 1991
31. Koopman G, Heider K-H, Horst E, et al: Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med 177:897-904, 1993
32. Matsumura Y, Tarin D: Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 340:1053-1058, 1992
33. Tanabe K, Ellis L, Saya H: Expression of CD44R1 adhesion molecule in colon carcinoma metastases. Lancet 341:725-726, 1993
34. Favrot MC, Lasset C, Combaret V: CD44: A new prognostic marker for neuroblastoma. N Engl J Med 329:1965, 1993
35. Gross N, Beretta C, Peruisseau G, et al: CD44H expression by human neuroblastoma cells: Relation to MYCN amplification and lineage differentiation. Cancer Res 54:4238-4242, 1994
36. Evans AE, D'Angio GJ, Randolph J: A proposed staging for children with neuroblastoma. Cancer 27:374-378, 1971
37. Philip T, Bernard JL, Zucker JM, et al: High-dose chemotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: An unselected group of stage IV patients over 1 year of age. J Clin Oncol 5:266-271, 1987
38. Zucker JM, Philip T, Bernard JL, et al. Single or double consolidation treatment according to remission status after initial therapy in metastatic neuroblastoma: First results of LMCE3 study in 40 patients, in Evans AE, D'Angio GJ, Knudson AG Jr, et al (eds): Advances in Neuroblastoma Research. 1991, pp 543-551
39. Thiesse P, Kaemmerien P, Bouffet E, et al: Percutaneous fine needle guided biopsies of the primary tumor in extensive neuroblastoma, in Evans AE, D'Angio GJ, Knudson AG Jr, et al (eds): New York, NY, Advances in Neuroblastoma Research. 1991, pp 503-507
40. Combaret V, Favrot MC, Kremens B, et al: Immunological detection of neuroblastoma cells in bone marrow harvested for autologous transplantation. Br J Cancer 59:844-847, 1989
41. Beck D, Maritaz O, Gross N, et al: Immunocytochemical detection of neuroblastoma cells infiltrating clinical bone marrow samples. Eur J Pediatr 147:609-612, 1988
42. Favrot MC, Combaret V, Goillot E, et al: Expression of integrin receptors on 45 clinical neuroblastoma specimens. Int J Cancer 49:347-355, 1991
43. Pesando JM, Hoffman P, Abed M: Antibody-induced antigenic modulation is antigen dependent: Characterization of 22 proteins on a malignant human B cell line. J Immunol 137:3689-3695, 1986
44. Dalchau R, Kirkley R, Fabre JW: Monoclonal antibody to a human brain-granulocyte T lymphocyte antigen probably homologous to the W3/13 antigen of the rat. Eur J Immunol 10:745-749, 1980
45. Kaplan ES, Meier P: Nonparametric estimations from incomplete observations. J Am Stat Assoc 53:457-481, 1958
46. Mantel H, Haenzel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
47. Favrot MC, Combaret V, Goillot E, et al: Expression of leucocyte adhesion molecules on 66 clinical neuroblastoma specimens. Int J Cancer 48:502-510, 1991
48. Gross N, Favre S, Beck D, et al: Differentiation-related expression of adhesion molecules and receptors on human neuroblastoma tissues, cell lines and variants. Int J Cancer 52:85-91, 1992
49. Stamenkovic I, Aruffo A, Amiot M, et al: The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J 10:343-348, 1991
50. Shtivelman E, Bishop M: Expression of CD44 is repressed in neuroblastoma cells. Mol Cell Biol 11:5446-5453, 1991
51. Haegel H, Tölg C, Hofmann M, et al: Activated mouse astrocytes and T cells express similar CD44 variants. Role of CD44 in astrocyte/T cell binding. J Cell Biol 122:1067-1077, 1993
52. Picker LJ, Nakache M, Butcher EC: Monoclonal antibodies to human lymphocyte homing receptor define a novel class of adhesion molecules on diverse cell types. J Cell Biol 109:927-937, 1989
53. Akeson R, Bernards R: Nmyc down regulates neural cell adhesion molecule expression in rat neuroblastoma. Mol Cell Biol 10:2012-2016, 1990